Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

Novartis Pharmaceuticals · 2019
ClinicalTrials.gov · Datasets · License: Public Domain · 2019
Open Source ↗
adultcognitive-assessmentconversionmultiple-sclerosis
multiple sclerosis, relapsing multiple sclerosis, advancing multiple sclerosis, conversion, siponimod, adult, baf312, disease modifying therapies, cognitive assessment, open-label, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 842856
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.